Drugs / BBI-940
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07408089 | Feb 2026 → Feb 2029 expected | breast cancer | Boundless Bio, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-04-17 | Boundless Bio, Inc. | Results Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting boundlessbio.com ↗
Our data demonstrate that selective degradation of this target delivered potent antitumor activity in validated breast cancer models, particularly those with ecDNA. |
| 2026-01-20 | Boundless Bio, Inc. | Regulatory Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway boundlessbio.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for its novel Kinesin oral degrader program, BBI-940. |
| 2025-05-23 | Boundless Bio, Inc. | Results Boundless Bio Announces Portfolio Prioritization and Runway Extension boundlessbio.com ↗
Based on these findings and market considerations, the Company has decided to discontinue further clinical development in the current arms of the POTENTIATE clinical trial. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-17 | Boundless Bio, Inc. | Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting boundlessbio.com ↗ |
| 2026-01-20 | Boundless Bio, Inc. | Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway boundlessbio.com ↗ |
| 2025-05-23 | Boundless Bio, Inc. | Boundless Bio Announces Portfolio Prioritization and Runway Extension boundlessbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBI-940 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07408089 ↗ |
| Modality | Small molecule | “Oral small molecule degrader targeting Kinesin.” NCT07408089 ↗ |
| Route | Oral | “BBI-940 is given orally in repeated 28-day cycles.” NCT07408089 ↗ |